Burning Rock Biotech (BNR) Equity Average (2020 - 2025)

Burning Rock Biotech's Equity Average history runs 6 years deep, the most recent figure standing at $76.3 million for Q4 2025.

• In Q4 2025, Equity Average fell 11.87% year-over-year to $76.3 million; the TTM figure through Dec 2025 stood at $76.3 million (down 11.87% YoY), while the FY2025 annual figure was $78.1 million, down 16.87% from the prior year.
• Equity Average was $76.3 million for Q4 2025 at Burning Rock Biotech, down from $78.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $360.8 million in Q1 2021 to a low of $76.3 million in Q4 2025.
• Historically, Equity Average has averaged $172.7 million across 5 years, with a median of $134.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Equity Average slumped 43.23% in 2022, then retreated 11.87% in 2025.
• A 5-year view of Equity Average shows it stood at $304.3 million in 2021, then plunged by 43.23% to $172.7 million in 2022, then tumbled by 34.87% to $112.5 million in 2023, then slipped by 23.01% to $86.6 million in 2024, then dropped by 11.87% to $76.3 million in 2025.
• The last three Equity Average figures came in at $76.3 million (Q4 2025), $78.0 million (Q3 2025), and $78.8 million (Q2 2025), per Business Quant data.